AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33694196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 0
Study 33694196 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 32109379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Number of subjects: 0
Study 32109379 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 35770629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 35770629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 34364382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS) and cancer-specific survival (CSS) based on independent prognostic factors including age, sex, tumor size, grade, chemotherapy, N stage, and M stage.
Number of subjects: 1196
Study 35739339 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial KiVa group (did not include the online game)
Number of subjects: 5923
Study 35739339 — intervention group
Group type: EXPERIMENTAL
Intervention: Full KiVa group (including the online game)
Number of subjects: 5923
Study 35739339 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular school curriculum)
Number of subjects: 5923
Study 33277281 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (FGM)
Number of subjects: 104
Study 33277281 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose
Number of subjects: 104
Study 35124807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene training (two sessions a week for 2 weeks)
Number of subjects: 134
Study 34584281 — intervention group
Group type: EXPERIMENTAL
Intervention: Baska Mask
Number of subjects: 84
Study 34584281 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 84
Study 35508084 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on positive references
Number of subjects: 40
Study 32450869 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 4983
Study 36617990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 269
Study 36617990 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 269
Study 33643416 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic score report (intervention group)
Number of subjects: 0
Study 33643416 — intervention group
Group type: COMPARATOR
Intervention: Overall percentage grade of performance (control group)
Number of subjects: 0
Study 33643416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 32681930 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic index based on Center of Mass Shift (COMshift) and 10th Intensity percentile (P10)
Number of subjects: 176
Study 32681930 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic index stratification by quartile values
Number of subjects: 176
Study 32681930 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic index validation cohort
Number of subjects: 176
Study 36143879 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion (TCI)
Number of subjects: 50
Study 36143879 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane inhalation
Number of subjects: 50
Study 36143879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 33152443 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical instrumental improvisation
Number of subjects: 87
Study 33152443 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical vocal improvisation
Number of subjects: 87
Study 33152443 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 87
Study 33152443 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal intervention
Number of subjects: 87
Study 33152443 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT)
Number of subjects: 87
Study 33514841 — intervention group
Group type: EXPERIMENTAL
Intervention: Forecasted economic anxiety
Number of subjects: 97
Study 33514841 — intervention group
Group type: COMPARATOR
Intervention: No-anxiety control condition
Number of subjects: 97
Study 33028319 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH Pregnancy Circles intervention
Number of subjects: 1732
Study 33028319 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1732
Study 35476124 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic tool to detect and reduce complexity of drug treatment
Number of subjects: 139
Study 33206382 — intervention group
Group type: EXPERIMENTAL
Intervention: 8U/kg abobotulinumtoxinA injections
Number of subjects: 210
Study 33206382 — intervention group
Group type: EXPERIMENTAL
Intervention: 16U/kg abobotulinumtoxinA injections
Number of subjects: 210
Study 33206382 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control 2U/kg)
Number of subjects: 210
Study 33206382 — intervention group
Group type: EXPERIMENTAL
Intervention: 8U/kg or 16U/kg abobotulinumtoxinA plus HETP
Number of subjects: 210
Study 33206382 — intervention group
Group type: COMPARATOR
Intervention: Control group (2U/kg)
Number of subjects: 210
Study 33206382 — intervention group
Group type: EXPERIMENTAL
Intervention: 8U/kg group
Number of subjects: 210
Study 33206382 — intervention group
Group type: EXPERIMENTAL
Intervention: 16U/kg group
Number of subjects: 210
Study 35064866 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration
Number of subjects: 14
Study 35064866 — intervention group
Group type: COMPARATOR
Intervention: Sham Aspiration
Number of subjects: 14
Study 33481875 — intervention group
Group type: EXPERIMENTAL
Intervention: French AmbUlatory Cesarean Section (FAUCS)
Number of subjects: 100
Study 33481875 — intervention group
Group type: COMPARATOR
Intervention: Misgav Ladach cesarean section (MLCS)
Number of subjects: 100
Study 33023849 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior osteotomy
Number of subjects: 20
Study 33023849 — intervention group
Group type: COMPARATOR
Intervention: Non-osteotomy
Number of subjects: 20
Study 33023849 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants with normal pelvic anatomy)
Number of subjects: 20
Study 35688588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led peer support intervention (6 weekly peer support sessions facilitated by a nurse and at least one peer facilitator)
Number of subjects: 120
Study 35688588 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly individual face-to-face sessions for 6 weeks)
Number of subjects: 120
Study 35688588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led peer support intervention
Number of subjects: 120
Study 35688588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 33080005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg up to 800 mg, intravenous within 8 hours from randomization, followed by a second dose after 12 hours)
Number of subjects: 126
Study 33080005 — intervention group
Group type: COMPARATOR
Intervention: Standard care (supportive care following clinical center protocols)
Number of subjects: 126
Study 33080005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 126
Study 33080005 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 126
Study 32847020 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based active games intervention with strengthening and jumping exercises for 24 weeks
Number of subjects: 111
Study 35213716 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 1628
Study 35213716 — intervention group
Group type: COMPARATOR
Intervention: Histamine-2 receptor blockers
Number of subjects: 1628
Study 33974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine appointment by a physician
Number of subjects: 112
Study 33974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine appointment by a medical assistant (RFA)
Number of subjects: 112
Study 33974131 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine consultation (both physician and RFA)
Number of subjects: 112
Study 33974131 — intervention group
Group type: COMPARATOR
Intervention: Vaccination behavior
Number of subjects: 112
Study 34334087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (8 weeks, 3 days/week) + diabetes and foot care education
Number of subjects: 37
Study 34334087 — intervention group
Group type: COMPARATOR
Intervention: Diabetes and foot care education only
Number of subjects: 37
Study 32086355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Wikipedia pages seeded with tables of best evidence and hyperlinks)
Number of subjects: 70
Study 32086355 — intervention group
Group type: COMPARATOR
Intervention: Control group (Wikipedia pages left unchanged)
Number of subjects: 70
Study 32185993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking and penetrating moxibustion therapy
Number of subjects: 60
Study 32185993 — intervention group
Group type: COMPARATOR
Intervention: Penetrating moxibustion therapy (Control)
Number of subjects: 60
Study 35202842 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational tools to engage local communities, building partnerships within local PD communities, and recruiting stakeholders to reimagine medical and research information for the community.
Number of subjects: 0
Study 35202842 — intervention group
Group type: COMPARATOR
Intervention: Control condition (specifics not provided).
Number of subjects: 0
Study 36223435 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 180
Study 36223435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 33841399 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cocktail
Number of subjects: 77
Study 33841399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 32078683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg tenecteplase (maximum, 40 mg; n = 150)
Number of subjects: 300
Study 32078683 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg/kg tenecteplase (maximum, 25 mg; n = 150)
Number of subjects: 300
Study 32078683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg tenecteplase
Number of subjects: 300
Study 32078683 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg/kg tenecteplase
Number of subjects: 300
Study 33526633 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 4540
Study 33208207 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa
Number of subjects: 57
Study 33208207 — intervention group
Group type: COMPARATOR
Intervention: Control (no recombinant factor VIIa)
Number of subjects: 57
Study 32379763 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab (RAM) plus paclitaxel (PAC)
Number of subjects: 0
Study 32379763 — intervention group
Group type: COMPARATOR
Intervention: placebo (PLA) plus paclitaxel (PAC)
Number of subjects: 0
Study 35493500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (maintenance therapy)
Number of subjects: 2
Study 35493500 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir, hyperimmune plasma, and corticosteroids (treatment during flares)
Number of subjects: 2
Study 33484269 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (90-second video featuring a young woman with schizophrenia)
Number of subjects: 1203
Study 33484269 — intervention group
Group type: EXPERIMENTAL
Intervention: Written vignette (description of the same content)
Number of subjects: 1203
Study 33484269 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control arm
Number of subjects: 1203
Study 33138171 — intervention group
Group type: EXPERIMENTAL
Intervention: Task Specific Training (TST) for the affected UL, one hour, three sessions per week for six weeks.
Number of subjects: 40
Study 35216037 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFN-β)
Number of subjects: 64
Study 35216037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 32788067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for Bell's palsy
Number of subjects: 644
Study 32788067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644
Study 35218604 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 25 mg alone
Number of subjects: 12
Study 35218604 — intervention group
Group type: COMPARATOR
Intervention: Trazpiroben 25 mg with esomeprazole 40 mg
Number of subjects: 12
Study 33439131 — intervention group
Group type: EXPERIMENTAL
Intervention: High modality interactivity and high message interactivity
Number of subjects: 293
Study 33439131 — intervention group
Group type: COMPARATOR
Intervention: Low message interactivity
Number of subjects: 293
Study 33439131 — intervention group
Group type: EXPERIMENTAL
Intervention: High modality interactivity
Number of subjects: 293
Study 33439131 — intervention group
Group type: EXPERIMENTAL
Intervention: High message interactivity
Number of subjects: 293
Study 32223086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg) plus tamsulosin hydrochloride (0.2 mg)
Number of subjects: 126
Study 32223086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg) only
Number of subjects: 126
Study 32223086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 32620020 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus nasogastric tube feeding
Number of subjects: 98
Study 32620020 — intervention group
Group type: COMPARATOR
Intervention: Bolus orogastric tube feeding
Number of subjects: 98
Study 32086898 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirolactone 20 mg orally twice a day for 7 days after H-UPPP
Number of subjects: 50
Study 35220140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 949
Study 35220140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 949
Study 35220140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 34259423 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group (n = 40)
Number of subjects: 80
Study 34259423 — intervention group
Group type: COMPARATOR
Intervention: non-ERAS group D (BMI ≥ 28 kg/m2, n = 22)
Number of subjects: 80
Study 32345377 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery combined with triptorelin acetate
Number of subjects: 0
Study 32345377 — intervention group
Group type: COMPARATOR
Intervention: Conservative surgery only
Number of subjects: 0
Study 36299392 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIIT)
Number of subjects: 18
Study 36299392 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 18
Study 36299392 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study 35304048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil + placebo
Number of subjects: 438
Study 35304048 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics + placebo
Number of subjects: 438
Study 35304048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil + probiotics
Number of subjects: 438
Study 35304048 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 438
Study 33935058 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 106
Study 33935058 — intervention group
Group type: EXPERIMENTAL
Intervention: HVPS
Number of subjects: 106
Study 33935058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 35551112 — intervention group
Group type: EXPERIMENTAL
Intervention: i-BFR30 (low intensity with intermittent BFR, ∼150 mm Hg)
Number of subjects: 12
Study 35551112 — intervention group
Group type: EXPERIMENTAL
Intervention: c-BFR30 (low intensity with continuous BFR, ∼100 mm Hg)
Number of subjects: 12
Study 35551112 — intervention group
Group type: EXPERIMENTAL
Intervention: HI (high intensity with unrestricted blood flow)
Number of subjects: 12
Study 35551112 — intervention group
Group type: EXPERIMENTAL
Intervention: All BFR conditions
Number of subjects: 12
Study 35551112 — intervention group
Group type: COMPARATOR
Intervention: CON30 (control, low intensity with unrestricted blood flow)
Number of subjects: 12
Study 34086101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 2779
Study 34086101 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2779
Study 34086101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2779
Study 32548624 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 233
Study 32548624 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 233
Study 34282866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment every 2 months for a total of 3 sessions
Number of subjects: 23
Study 32811402 — intervention group
Group type: EXPERIMENTAL
Intervention: Insall-Salvati Index (ISI) measurement
Number of subjects: 45
Study 33004277 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D immunoglobulin (RhIg) prophylaxis
Number of subjects: 0
Study 33004277 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg treatment
Number of subjects: 0
Study 34526250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (study group)
Number of subjects: 100
Study 34526250 — intervention group
Group type: COMPARATOR
Intervention: Control group (without RA)
Number of subjects: 100
Study 32020731 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 481
Study 32020731 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose
Number of subjects: 481
Study 35181553 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized call center for death event identification
Number of subjects: 2284
Study 35181553 — intervention group
Group type: COMPARATOR
Intervention: National Death Index (NDI)
Number of subjects: 2284
Study 35181553 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized call center
Number of subjects: 2284
Study 35181553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen's kappa coefficient
Number of subjects: 2284
Study 33960540 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced (LR) packed red blood cells (PRBC)
Number of subjects: 194
Study 33960540 — intervention group
Group type: COMPARATOR
Intervention: Nonleukoreduced (N-LR) packed red blood cells (PRBC)
Number of subjects: 194
Study 33096736 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 49
Study 33096736 — intervention group
Group type: COMPARATOR
Intervention: Hospital monitoring
Number of subjects: 49
Study 36250647 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for families of youth with type 1 diabetes over 2 years
Number of subjects: 390
Study 33241960 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT2506
Number of subjects: 180
Study 33241960 — intervention group
Group type: COMPARATOR
Intervention: golimumab
Number of subjects: 180
Study 35087707 — intervention group
Group type: EXPERIMENTAL
Intervention: Institution based cardiac rehabilitation (IBCR)
Number of subjects: 100
Study 35087707 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based cardiac rehabilitation (HBCR)
Number of subjects: 100
Study 35087707 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Observational arm)
Number of subjects: 100
Study 33590901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nitazoxanide, ribavirin, and ivermectin plus Zinc supplement
Number of subjects: 113
Study 33590901 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 113
Study 35403398 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser moxibustion
Number of subjects: 76
Study 35403398 — intervention group
Group type: COMPARATOR
Intervention: Sham laser moxibustion
Number of subjects: 76
Study 34264861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hicaz maqam music for 30 minutes a day for a week
Number of subjects: 87
Study 34264861 — intervention group
Group type: EXPERIMENTAL
Intervention: Huseyni maqam music for 30 minutes a day for a week
Number of subjects: 87
Study 34264861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 33300290 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-high sodium (n = 199)
Number of subjects: 588
Study 33300290 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-low sodium (n = 196)
Number of subjects: 588
Study 33300290 — intervention group
Group type: COMPARATOR
Intervention: Control-high sodium (n = 193)
Number of subjects: 588
Study 33300290 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-high sodium
Number of subjects: 588
Study 33300290 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-low sodium
Number of subjects: 588
Study 32315461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-conducted medication review
Number of subjects: 10565
Study 32315461 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Burden Index (DBI) assessment
Number of subjects: 10565
Study 32315461 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of falling assessment
Number of subjects: 10565
Study 35960166 — intervention group
Group type: COMPARATOR
Intervention: Real neurofeedback (n=12)
Number of subjects: 24
Study 35960166 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback (n=12)
Number of subjects: 24
Study 34607238 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative media item on lamotrigine
Number of subjects: 108
Study 34607238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo explanation
Number of subjects: 108
Study 34607238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 32092717 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol patch
Number of subjects: 240
Study 32092717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 35780813 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 convalescent plasma (n=487)
Number of subjects: 974
Study 35780813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=473)
Number of subjects: 974
Study 35780813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=465)
Number of subjects: 974